Tvm Life Science Ventures Vi LP
recently revealed that they own a 11.6% stake in Proteon Therapeutics, Inc. (NASDAQ:PRTO) in a Schedule 13D/A disclosure that was filed with the Securities and Exchange Commission (SEC) on Wednesday, August 2nd. The investor owns 1,943,059 shares of the stock worth $2,525,977. The reporting parties listed on the disclosure included TVM Life Science Ventures VI LP, TVM Life Science Ventures VI GmbH & Co KG, TVM Life Science Ventures Management VI LP, Hubert Birner, Stefan Fischer and Helmut Schuehsler. The disclosure is available through Edgar at this hyperlink.
Tvm Life Science Ventures Vi LP
provided the following explanation of their ownership:
Warning: file_get_contents(): php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6
): failed to open stream: php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6
Shares of Proteon Therapeutics, Inc. (NASDAQ:PRTO) traded down 3.70% during midday trading on Friday, hitting $1.30. 49,015 shares of the company were exchanged. The company’s 50 day moving average price is $1.38 and its 200 day moving average price is $1.54. Proteon Therapeutics, Inc. has a one year low of $1.10 and a one year high of $11.45. The firm’s market cap is $22.90 million.
Proteon Therapeutics (NASDAQ:PRTO) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.11. Equities analysts expect that Proteon Therapeutics, Inc. will post ($1.55) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Rincon Hill News and is the property of of Rincon Hill News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://rinconhillneighbors.org/2017/08/12/11-6-stake-of-proteon-therapeutics-inc-nasdaqprto-owned-by-tvm-life-science-ventures-vi-lp-updated.html.
Several analysts have issued reports on PRTO shares. Maxim Group set a $6.00 price objective on shares of Proteon Therapeutics and gave the company a “buy” rating in a research report on Thursday, May 4th. HC Wainwright set a $3.00 price target on shares of Proteon Therapeutics and gave the stock a “hold” rating in a research report on Saturday, May 13th. Zacks Investment Research downgraded shares of Proteon Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 17th. Finally, Cowen and Company reissued a “hold” rating on shares of Proteon Therapeutics in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company’s stock. Proteon Therapeutics has an average rating of “Hold” and an average price target of $8.00.
About Proteon Therapeutics
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with our FREE daily email newsletter.